Xian Janssen

Since Xian Janssen Pharmaceutical Ltd. brought the first batch of drugs to China in 1985, Xian Janssen has been committed to researching, introducing, and producing high-quality medicines and innovative pharmaceutical solutions to meet China's growing healthcare needs. As one of the earliest established multinational pharmaceutical enterprises and Johnson & Johnson's largest pharmaceutical subsidiary in China, Xian Janssen's products cover nine major disease areas: psychiatry, neurology, colds, coughs, fever/digestive issues, dermatology/anti-allergy, hematology, immunology, solid tumors, infectious diseases, and pulmonary hypertension.For more than 30 years, we have witnessed and participated in the vigorous development of China's healthcare system. As an active corporate citizen, we continuously seek cooperation in areas such as pharmaceuticals, public health, drug research and development, public welfare practices, and sustainable development, joining hands with like-minded individuals to fulfill our commitment to giving back to society and contributing social value.By 2018, we had established offices in 29 cities across China, with nearly 3,000 employees. Guided by our company’s credo and spirit of care, we have built a sustainable talent development system to help employees realize diverse values and achieve growth.